The LUME-Lung @ trial ( NCT@ ; Study @ ) demonstrated a significant overall survival ( OS ) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell lung cancer ( NSCLC ) and adenocarcinoma histology .